Are there unknown mineralocorticoids in low-renin essential hypertension? 1977

J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle

The blood pressure elevation of primary aldosteronism is caused by excessive production of the known mineralocorticoid, aldosterone. The blood pressure elevation of low-renin essential hypertension may also be caused by mineralocorticoid excess, but which which mineralocorticoid is responsible is uncertain. Normal levels of aldosterone, found in this disorder despite suppressed plasma renin, and the presence of an unknown mineralocorticoid have been hypothesized to explain low-renin essential hypertension. We contrasted the blood pressure responses and changes in aldosterone seen in patients with low-renin essential hypertension and primary aldosteronism during treatment with two adrenal enzyme inhibitors. The results demonstrate the similarity between decrease in blood pressure and in aldosterone during early adrenal inhibition in both primary aldosteronism and in low-renin essential hypertension. During treatment with a distal adrenal blocker, patients with primary aldosteronism demonstrated decreases in both aldosterone and blood pressure, whereas patients with low-renin essential hypertension showed a decrease in aldosterone without significant change in blood pressure. This suggested that aldosterone was not the major mineralocorticoid responsible for low-renin essential hypertension. Unknown mineralocorticoid excretion decreased (along with blood pressure) during early inhibition but failed to decrease (along with blood pressure) during late inhibition at a time when aldosterone excretion decreased. This suggests that unknown mineralocorticoids play significant roles in the blood pressure elevation of low-renin essential hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008797 Metyrapone An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME. Methbipyranone,Methopyrapone,Metopiron,Metopirone,Métopirone,SU 4885
D008901 Mineralocorticoids A group of CORTICOSTEROIDS primarily associated with water and electrolyte balance. This is accomplished through the effect on ION TRANSPORT in renal tubules, resulting in retention of sodium and loss of potassium. Mineralocorticoid secretion is itself regulated by PLASMA VOLUME, serum potassium, and ANGIOTENSIN II. Mineralocorticoid,Mineralocorticoid Effect,Mineralocorticoid Effects,Effect, Mineralocorticoid,Effects, Mineralocorticoid
D011187 Posture The position or physical attitude of the body. Postures
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's
D000616 Aminoglutethimide An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER. Cytadren,Orimeten

Related Publications

J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
March 1974, Journal of the Tennessee Medical Association,
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
November 1973, Nihon rinsho. Japanese journal of clinical medicine,
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
April 1973, L'union medicale du Canada,
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
November 1979, Annals of clinical biochemistry,
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
September 1983, Clinical pharmacology and therapeutics,
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
July 1990, Kardiologiia,
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
January 1983, Hypertension (Dallas, Tex. : 1979),
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
March 1980, Recenti progressi in medicina,
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
September 1999, Hypertension (Dallas, Tex. : 1979),
J W Hollifield, and P E Slaton, and H M Wilson, and J A Sennett, and L Yarbro, and D P Island, and G W Liddle
July 1978, Clinical nuclear medicine,
Copied contents to your clipboard!